A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Status:
Recruiting
Trial end date:
2023-10-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability and efficacy (objective response rate) of
using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab
alone in subjects with advanced/metastatic melanoma.